# ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

Source: https://onco.cc/trials/nct04986423/  
OnCo record `nct04986423` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ZEN-3694, Enzalutamide in prostate cancer, run by Zenith Epigenetics, now recruiting.

## Summary

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer is a phase 2 interventional study registered as NCT04986423 by Zenith Epigenetics, with 200 participants planned, started 2021-09-08 and due to reach its primary completion in 2026-12. Interventions recorded: ZEN003694, Enzalutamide. Conditions listed: Metastatic Castration-Resistant Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04986423
- Phase: 2
- Setting: A Randomized Phase 2b Study of ZEN003694 in Combination With Enzalutamide Versus Enzalutamide Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- Sponsor: Zenith Epigenetics
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT04986423: https://clinicaltrials.gov/study/NCT04986423

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Enzalutamide](https://onco.cc/drugs/enzalutamide/), [ZEN-3694](https://onco.cc/drugs/zen-3694/)

---
JSON: https://onco.cc/api/v1/entities/nct04986423.json